Progress in Myelodysplastic Syndromes

During the past 5 years, we have witnessed an explosion in our understanding, classification, and number of therapeutic opportunities for patients with myelodysplastic syndromes (MDS). These include the development of new histologic classifications, scoring systems, supportive care measures, and most importantly, effective treatments that are safe and can modify the natural history of this complex group of hematopoietic disorders. In this brief review, and as part of the Leukemia 2008, Fourth International Conference, held in Houston during September 2008, I summarize some of the most important recent developments in the field of MDS and try to identify new problems and opportunities for patients and researchers in this area.